JP2012514465A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012514465A5 JP2012514465A5 JP2011544917A JP2011544917A JP2012514465A5 JP 2012514465 A5 JP2012514465 A5 JP 2012514465A5 JP 2011544917 A JP2011544917 A JP 2011544917A JP 2011544917 A JP2011544917 A JP 2011544917A JP 2012514465 A5 JP2012514465 A5 JP 2012514465A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide according
- disease
- polypeptide
- seq
- biological activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 101710191541 Chemotaxis inhibitory protein Proteins 0.000 claims 5
- 230000004071 biological effect Effects 0.000 claims 5
- 206010000891 acute myocardial infarction Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000037187 Autoimmune Experimental Neuritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003267 Arthritis reactive Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 208000000104 Arthus reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 108010078546 Complement C5a Proteins 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000001034 Frostbite Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010054272 Helicobacter gastritis Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 102220267471 c.299A>G Human genes 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 102220219966 rs749886101 Human genes 0.000 claims 1
- 102220342070 rs757377148 Human genes 0.000 claims 1
- 102220118568 rs76784312 Human genes 0.000 claims 1
- 102220324698 rs773305634 Human genes 0.000 claims 1
- 102220059793 rs786202542 Human genes 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19392609P | 2009-01-08 | 2009-01-08 | |
| US61/193,926 | 2009-01-08 | ||
| GB0905790.2 | 2009-04-03 | ||
| GBGB0905790.2A GB0905790D0 (en) | 2009-04-03 | 2009-04-03 | Novel polypeptides and use thereof |
| PCT/GB2009/002782 WO2010079314A2 (en) | 2009-01-08 | 2009-11-30 | Novel polypeptides and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012514465A JP2012514465A (ja) | 2012-06-28 |
| JP2012514465A5 true JP2012514465A5 (enExample) | 2013-01-24 |
Family
ID=40750044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011544917A Pending JP2012514465A (ja) | 2009-01-08 | 2009-11-30 | 新規なポリペプチドおよびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8552149B2 (enExample) |
| EP (1) | EP2373683A2 (enExample) |
| JP (1) | JP2012514465A (enExample) |
| CN (1) | CN102348719A (enExample) |
| AU (1) | AU2009336610A1 (enExample) |
| BR (1) | BRPI0923938A2 (enExample) |
| CA (1) | CA2748522A1 (enExample) |
| GB (1) | GB0905790D0 (enExample) |
| RU (1) | RU2011133060A (enExample) |
| WO (1) | WO2010079314A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0607798D0 (en) * | 2006-04-20 | 2006-05-31 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| JP7502865B2 (ja) * | 2017-06-23 | 2024-06-19 | インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｃ５ａ活性のインヒビターでの炎症性疾患の処置 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IN151589B (enExample) | 1978-12-22 | 1983-05-28 | Biogen Nv | |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| CA2072249C (en) | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| AU3559695A (en) | 1994-09-30 | 1996-04-26 | Inex Pharmaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
| US5545531A (en) | 1995-06-07 | 1996-08-13 | Affymax Technologies N.V. | Methods for making a device for concurrently processing multiple biological chip assays |
| GB9712512D0 (en) | 1997-06-16 | 1997-08-20 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| CA2333898A1 (en) | 1998-07-10 | 2000-01-20 | Jari Pharmaceuticals B.V. | Chemotaxis-inhibiting protein of staphylococcus (chips) and its use |
| EP1118663A1 (en) * | 2000-01-07 | 2001-07-25 | Universiteit Utrecht | Nucleic acids encoding chemotaxis inhibitory polypeptides |
| JP4430303B2 (ja) | 2000-12-12 | 2010-03-10 | アリゲーター・バイオサイエンス・アーベー | タンパク質機能のインビトロ分子進化方法 |
| US7262012B2 (en) | 2002-05-17 | 2007-08-28 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations |
| EP1586583A3 (en) | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Compounds that block C5a complement receptor and their use in therapy |
| GB2432366B (en) | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| GB0607798D0 (en) * | 2006-04-20 | 2006-05-31 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
-
2009
- 2009-04-03 GB GBGB0905790.2A patent/GB0905790D0/en not_active Ceased
- 2009-11-30 CA CA2748522A patent/CA2748522A1/en not_active Abandoned
- 2009-11-30 JP JP2011544917A patent/JP2012514465A/ja active Pending
- 2009-11-30 EP EP09768216A patent/EP2373683A2/en not_active Withdrawn
- 2009-11-30 US US13/142,835 patent/US8552149B2/en not_active Expired - Fee Related
- 2009-11-30 RU RU2011133060/10A patent/RU2011133060A/ru unknown
- 2009-11-30 BR BRPI0923938A patent/BRPI0923938A2/pt not_active IP Right Cessation
- 2009-11-30 AU AU2009336610A patent/AU2009336610A1/en not_active Abandoned
- 2009-11-30 WO PCT/GB2009/002782 patent/WO2010079314A2/en not_active Ceased
- 2009-11-30 CN CN2009801579165A patent/CN102348719A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012514465A5 (enExample) | ||
| JP2012533288A5 (enExample) | ||
| CA2997539C (en) | A novel endolysin polypeptide | |
| JP2013520979A5 (enExample) | ||
| CN104231085A (zh) | 靶向特异性补体系统抑制剂、其制备方法及应用 | |
| EP2899271A1 (en) | Protein ligand for affinity isolation matrix | |
| US20110081707A1 (en) | Lactobacillus acidophilus nucleic acid sequences encoding carbohydrate utilization-related proteins and uses therefor | |
| Jedrzejas et al. | Production and characterization of the functional fragment of pneumococcal surface protein A | |
| JP2008539750A5 (enExample) | ||
| JPWO2020092830A5 (enExample) | ||
| JP2013505030A5 (enExample) | ||
| RU2011133060A (ru) | Новые полипептиды и их применение | |
| CN109628457A (zh) | 单链dna核酸适配体及其筛选方法与用途 | |
| Zheng et al. | Ferritin has an important immune function in the ark shell Scapharca broughtonii | |
| JP2017537888A5 (enExample) | ||
| Huang et al. | SAAV2152 is a single-stranded DNA binding protein: The third SSB in Staphylococcus aureus | |
| CN104805104B (zh) | 一种海藻糖合酶及其编码基因与应用 | |
| CN108129555A (zh) | 特异性结合铜绿假单胞菌六型分泌系统免疫蛋白的多肽的设计及其抗菌活性的验证 | |
| WO2007122400A2 (en) | Novel polypeptides and use thereof | |
| Patro et al. | Utilization of plant-derived recombinant human β-defensins (hBD-1 and hBD-2) for averting salmonellosis | |
| Andre et al. | Glucose and trehalose PTS permeases of Spiroplasma citri probably share a single IIA domain, enabling the spiroplasma to adapt quickly to carbohydrate changes in its environment | |
| CN101121935B (zh) | 栉孔扇贝丝氨酸蛋白酶抑制剂CfKZSPI基因及其编码蛋白和应用 | |
| Kumar Megta et al. | SpaB, an atypically adhesive basal pilin from the lactobacillar SpaCBA pilus: crystallization and X-ray diffraction analysis | |
| Xie et al. | Transcriptional responses of Haemophilus parasuis to iron-restriction stress in vitro | |
| Xu et al. | A conserved fold for fimbrial components revealed by the crystal structure of a putative fimbrial assembly protein (BT1062) from Bacteroides thetaiotaomicron at 2.2 Å resolution |